Yuehong Wang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2417907/publications.pdf Version: 2024-02-01



YUEHONG WANG

#	Article	IF	CITATIONS
1	A Classifier for Improving Early Lung Cancer Diagnosis Incorporating Artificial Intelligence and Liquid Biopsy. Frontiers in Oncology, 2022, 12, 853801.	2.8	9
2	TROY Modulates Cancer Stem-Like Cell Properties and Gefitinib Resistance Through EMT Signaling in Non–Small Cell Lung Cancer. Frontiers in Genetics, 2022, 13, .	2.3	1
3	International consensus on severe lung cancer—the first edition. Translational Lung Cancer Research, 2021, 10, 2633-2666.	2.8	6
4	Mechanism of acquired resistance to nivolumab in lung squamous cell carcinoma: case report and review of the literature. Immunotherapy, 2020, 12, 957-964.	2.0	7
5	Investigation on the prognostic impact of concurrent genomic alterations in crizotinib-treated EML4-ALK-rearranged advanced non-small cell lung cancer patients. Lung Cancer, 2020, 146, 209-216.	2.0	2
6	Identify driver mutants in lung cancer by supernatants of pleural effusion and monitor resistance to targeted therapy Journal of Clinical Oncology, 2019, 37, e14554-e14554.	1.6	0
7	Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment. BMC Cancer, 2018, 18, 10.	2.6	28
8	Polo-like kinase 1 inhibitor BI 6727 induces DNA damage and exerts strong antitumor activity in small cell lung cancer. Cancer Letters, 2018, 436, 1-9.	7.2	18
9	Regulation of Viral Infection-induced Airway Remodeling Cytokine Production by the TLR3-EGFR Signaling Pathway in Human Bronchial Epithelial Cells. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2016, 13, 750-755.	1.6	8
10	HB-EGF–Promoted Airway Smooth Muscle Cells and Their Progenitor Migration Contribute to Airway Smooth Muscle Remodeling in Asthmatic Mouse. Journal of Immunology, 2016, 196, 2361-2367.	0.8	21
11	Epithelial–Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor–Mediated Apoptosis in Non–Small Cell Lung Cancer. Clinical Cancer Research, 2016, 22, 1674-1686.	7.0	41
12	Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with <i>T790M</i> mutations. Oncotarget, 2016, 7, 47998-48010.	1.8	21
13	A marked response to icotinib in a patient with large cell neuroendocrine carcinoma harboring an EGFR mutation: A case report. Oncology Letters, 2015, 10, 1575-1578.	1.8	20
14	Evaluation of the factors affecting the maximum standardized uptake value of metastatic lymph nodes in different histological types of non-small cell lung cancer on PET-CT. BMC Pulmonary Medicine, 2015, 15, 20.	2.0	17
15	Clinical Features and Gene Mutations of Lung Cancer Patients 30 Years of Age or Younger. PLoS ONE, 2015, 10, e0136659.	2.5	13
16	Triggering receptor expressed on myeloid cells-2 (TREM-2) elicited by lung cancer cells to facilitate tumor immune evasion Journal of Clinical Oncology, 2013, 31, e22054-e22054.	1.6	2